{"id":"azacytidine-hag-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azacytidine inhibits DNA methylation by incorporating into DNA and trapping DNA methyltransferase, leading to hypomethylation of DNA. This reactivates silenced tumor suppressor genes and promotes cellular differentiation. The HAG regimen combines azacytidine with homoharringtonine and arsenic trioxide for enhanced anti-leukemic activity in hematologic malignancies.","oneSentence":"Azacytidine is a DNA methyltransferase inhibitor that demethylates DNA and promotes differentiation of myelodysplastic cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:42:51.714Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myelodysplastic syndromes"},{"name":"Acute myeloid leukemia (as part of HAG combination regimen)"}]},"trialDetails":[{"nctId":"NCT05029141","phase":"PHASE2","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-09-01","conditions":"Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML","enrollment":21},{"nctId":"NCT04248595","phase":"PHASE2","title":"Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML","status":"UNKNOWN","sponsor":"Ge Zheng","startDate":"2019-12-01","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT03873311","phase":"PHASE4","title":"Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy","status":"UNKNOWN","sponsor":"Shenzhen Second People's Hospital","startDate":"2019-09-01","conditions":"Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia","enrollment":114},{"nctId":"NCT04722952","phase":"PHASE3","title":"PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-05-01","conditions":"Immunotherapy, Refractory Leukemia, Relapsed Adult AML","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Azacytidine, HAG Regimen (HHT Cytarabine G-CSF)"],"phase":"marketed","status":"active","brandName":"Azacytidine, HAG Regimen","genericName":"Azacytidine, HAG Regimen","companyName":"Shenzhen Second People's Hospital","companyId":"shenzhen-second-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azacytidine is a DNA methyltransferase inhibitor that demethylates DNA and promotes differentiation of myelodysplastic cells. Used for Myelodysplastic syndromes, Acute myeloid leukemia (as part of HAG combination regimen).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}